NeoGenomics, a provider of oncology testing services, has acquired Pathline, a CLIA/CAP/NYS-certified laboratory based in New Jersey.
The acquisition strengthens NeoGenomics’ commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence for the company in a historically under penetrated but rapidly growing geographical region of the country.
Founded in 2009, Pathline serves a long-standing client base of hospitals, cancer centers, and physician practices, with approximately 98% of its revenue coming from customers in the Northeast. It offers a comprehensive suite of subspecialty pathology services, including histopathology, immunohistochemistry, cytology, cytogenetics, flow cytometry, fluorescence in situ hybridization (FISH), and molecular pathology.
“The acquisition of Pathline presents a strategic opportunity because it brings New York State (NYS) approvals and when combined with our rapid turnaround times and leading customer experience will enable us to accelerate growth to what has historically been an underpenetrated region,” said Warren Stone, Chief Commercial Officer at NeoGenomics.
“We have deeper penetration rates in areas where we have close proximity to a lab like California, Florida and Texas. Integrating Pathline’s operations into NeoGenomics’ national network will further enhance our ability to support oncologists, healthcare institutions and patients in the Northeast region.”
“As part of NeoGenomics, we are excited to leverage our expertise and strong oncology testing capabilities to reach more patients and healthcare providers,” said Dr. Zach Liu, Chief Medical Officer and Laboratory Director at Pathline.
“Our team has built a trusted laboratory serving hospitals and oncology practices across the Northeast, and we look forward to continuing to improve cancer care by expanding access to advanced molecular testing for the patients that we serve under the NeoGenomics banner moving forward.”
